Glaukos, Santen expand microshunt agreement
Glaukos and Santen have entered a new license agreement for the development and commercialization of the PreserFlo microshunt, replacing the previous agreements between the companies, according to a press release.
The agreement grants Glaukos commercialization rights for the microshunt in the United States, Australia, New Zealand, Canada, Brazil, Mexico and the rest of Latin America, the release said. Additionally, Glaukos receives control of all development activities for the microshunt in those territories, as well as all clinical development and regulatory duties in the United States after a transition period, the release said.
“We are excited to expand our agreement with Santen for the microshunt, supporting our goal to bring this important late-stage glaucoma technology to ophthalmic surgeons and patients,” Thomas Burns, president and CEO of Glaukos, said in the release.
Santen will manufacture and supply the microshunt for Glaukos territories and will lead commercialization and development efforts outside of those areas, the release said.
Santen submitted a premarket approval application for the microshunt to the FDA in June 2020.